Kevin Bitterman - 30 Jul 2025 Form 4 Insider Report for Disc Medicine, Inc. (IRON)

Role
Director
Signature
/s/ Ommer Chohan, Attorney-in-Fact
Issuer symbol
IRON
Transactions as of
30 Jul 2025
Transactions value $
-$518,352
Form type
4
Filing time
01 Aug 2025, 16:32:51 UTC
Previous filing
25 Jul 2025
Next filing
07 Aug 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Bitterman Kevin Director C/O DISC MEDICINE, INC., 321 ARSENAL STREET, SUITE 101, WATERTOWN /s/ Ommer Chohan, Attorney-in-Fact 01 Aug 2025 0001591747

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IRON Common Stock Sale -$518K -8.49K -1.34% $61.04 625K 30 Jul 2025 See footnote F1, F2, F3
holding IRON Common Stock 421K 30 Jul 2025 See footnote F4
holding IRON Common Stock 51K 30 Jul 2025 See footnote F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Shares were sold pursuant to a Rule 10b5-1 trading plan dated January 31, 2025.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.95 to $61.35 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 These shares are held by Atlas Venture Opportunity Fund I, LP ("Opportunity I"). The general partner of Opportunity I is Atlas Venture Associates Opportunity I, LP ("Associates I"). Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. The Reporting Person is a member of Associates I LLC and disclaims beneficial ownership of such securities held by Opportunity I, except to the extent of his pecuniary interest therein, if any.
F4 These shares are held by Atlas Venture Opportunity Fund II, LP ("Opportunity II"). The general partner of Opportunity II is Atlas Venture Associates Opportunity II, LP ("Associates II"). Atlas Venture Associates Opportunity II, LLC ("Associates II LLC") is the general partner of Associates II. The Reporting Person is a member of Associates II LLC and disclaims beneficial ownership of such securities held by Opportunity II, except to the extent of his pecuniary interest therein, if any.
F5 These shares are held by Atlas Venture Fund XII, L.P. ("Atlas XII"). The general partner of Atlas XII is Atlas Venture Associates XII, L.P. ("Associates XII"). Atlas Venture Associates XII, LLC ("Associates XII LLC") is the general partner of Associates XII. The Reporting Person is a member of Associates XII LLC and disclaims beneficial ownership of such securities held by Atlas XII, except to the extent of his pecuniary interest therein, if any.